Psittacosis is a zoonotic infection caused by the obligate intracellular bacterium Chlamydia psittaci, transmitted primarily through inhalation of aerosolized bird droppings, feathers, or respiratory secretions. It presents as a community-acquired pneumonia (CAP) ranging from mild flu-like illness to fulminant respiratory failure with multi-organ dysfunction. The incubation period is 7–14 days. [1-2] It is frequently underdiagnosed due to nonspecific symptoms and lack of routine diagnostic testing. [3-4]
1. History
- Exposure history is the single most important HPI element: Ask specifically about contact with parrots, parakeets, cockatiels, pigeons, poultry (chickens, ducks, turkeys), or wild birds — including pet stores, bird fairs, farms, slaughterhouses, and backyard flocks [3][5-6]
- Even brief or indirect exposure (cleaning coops, walking through contaminated areas) can transmit infection; ~50–88% of confirmed cases report avian/poultry contact [5][7]
- Symptom onset typically 7–14 days after exposure; median incubation ~11 days (range 6–22 days) [1-2]
- Characterize: abrupt onset of high fever (often ≥39°C), dry cough, headache (often severe/prominent), myalgia, fatigue, dyspnea, chills [3][5][8]
- Extrapulmonary symptoms: GI complaints (diarrhea, nausea — 15.6%), CNS symptoms (confusion, lethargy — 36.9%), chest tightness [5]
- Important negatives: lack of improvement on beta-lactam antibiotics is a key diagnostic clue [3]
2. Alarm Features
- Dyspnea, tachypnea, or hypoxia — up to 42.6% meet criteria for severe CAP [5]
- Altered mental status / consciousness disorders — independently associated with severe disease [9]
- Rapid clinical deterioration despite empiric beta-lactam therapy [3]
- Bilateral lung involvement and pleural effusion — significantly more common in severe cases (76.2% vs 45.3%) [7]
- Elevated D-dimer, markedly reduced lymphocyte percentage, and elevated LDH predict severe disease [7][10]
- Myocardial injury — independent risk factor for severe psittacosis (OR 124.3) [9]
- Cardiac arrest, ARDS, and multi-organ failure have been reported [11-12]
3. Medications
- First-line: Doxycycline — 100 mg PO/IV every 12 hours. Treatment duration typically 10–21 days depending on severity [13-14]
- Alternative: Fluoroquinolones (moxifloxacin 400 mg daily) — effective but tetracyclines demonstrate higher cure rates (95.7% vs 31.0%) and faster defervescence [5]
- Macrolides (azithromycin) — second-line alternative, particularly in pregnancy or children <8 years
- In severe/ICU cases: doxycycline + moxifloxacin combination is commonly used [15]
- Tigecycline or omadacycline have been used successfully in severe cases [16-17]
- Beta-lactams are ineffective — C. psittaci is an obligate intracellular organism; failure to improve on beta-lactams should raise suspicion [3]
- Contraindicated: Doxycycline in pregnancy (use azithromycin); caution in children <8 years
4. Diet
- No specific dietary triggers or restrictions
- Maintain adequate hydration, especially with high fevers
- Monitor for hypoalbuminemia (common in severe cases) — nutritional support may be needed in ICU patients [11][18]
- Avoid taking doxycycline with dairy products, antacids, or iron supplements (chelation reduces absorption)
5. Review of Systems
- Respiratory: cough (63%), dyspnea (50%), chest tightness, pleuritic pain [5]
- Constitutional: fever (94–100%), chills (38%), fatigue (30–53%), myalgia (30%) [5][7]
- Neurologic: headache (often severe and disproportionate), confusion, lethargy — CNS symptoms in ~37%; meningitis has been reported [5][19]
- GI: diarrhea, nausea, poor appetite (~16%) [5]
- Hepatic: hepatic dysfunction in up to 87.5% of cases (elevated AST/ALT) [16]
- Cardiac: palpitations, chest pain — screen for myocarditis/pericarditis [20]
- Renal: AKI occurs in 34% of psittacosis cases vs 12% in typical CAP [17]
6. Collateral History and Family History
- Household bird/poultry exposure: all household members with shared avian contact should be evaluated [6][15]
- Occupational exposure: poultry workers, veterinarians, pet shop employees, bird breeders, slaughterhouse workers [4][21]
- Human-to-human transmission is rare but documented, particularly from severely ill patients — a Swedish outbreak demonstrated transmission from one patient to 10 contacts including healthcare workers; a Chinese investigation confirmed secondary and tertiary human-to-human transmission including via asymptomatic carriers [22-23]
- Family clusters have been reported with shared poultry exposure [6][15]
7. Risk Factors
- Bird/poultry contact — the dominant risk factor (reported in 50–88% of cases) [5][7]
- Age >65 years and male sex — independent risk factors for severe pneumonia [5]
- Underlying comorbidities — chronic cardiac disease (especially DCM), immunosuppression [18][24]
- Occupational: poultry processing, farming, veterinary work, pet bird ownership [4][21]
- Seasonal: peak incidence in autumn/winter (September–April) [5][25]
- Delayed diagnosis — longer time from onset to diagnosis correlates with severity (8 vs 14 days) [9]
8. Differential Diagnosis
- Legionella pneumonia — the closest mimic; both cause atypical CAP with high fever, systemic symptoms, and elevated inflammatory markers. Distinguishing features: Legionella has more severe cough, higher WBC, and higher glucose; psittacosis has more relative bradycardia, higher CK, and bird exposure [26-28]
- Mycoplasma pneumoniae — typically milder, younger patients, less systemic inflammation
- Chlamydia pneumoniae — similar atypical pneumonia but no avian exposure link
- Q fever (Coxiella burnetii) — livestock exposure rather than birds; hepatitis more prominent
- Influenza / COVID-19 — viral pneumonia; rapid antigen/PCR testing differentiates
- Tuberculosis — subacute course, upper lobe predominance, cavitation
- Pulmonary embolism — consider with elevated D-dimer and dyspnea
- Cannot-miss: Legionella (high mortality if untreated), TB, PE
9. Past Medical History
- Pre-existing cardiac disease — DCM patients at risk for cardiogenic shock with psittacosis [24]
- Chronic lung disease — may worsen respiratory failure
- Immunosuppression — increased risk of severe/fulminant course
- Previous episodes — recurrence is possible with re-exposure
- Prior antibiotic use — failure of beta-lactams is a diagnostic clue [3]
10. Physical Exam
- Vital signs: High fever (often ≥39.5°C), relative bradycardia (present in ~80% — a classic finding), tachypnea, hypoxia [27]
- Pulmonary: Crackles/rales on auscultation; may have dullness to percussion with consolidation or effusion; exam may be deceptively benign relative to imaging
- Hepatosplenomegaly — classically described (Horder spots — rare macular rash)
- Neurologic: Assess for altered mental status, meningismus [19]
- Cardiac: Murmur (consider endocarditis in culture-negative cases with bird exposure) [20][29]
- Skin: Rarely, erythema nodosum or macular rash
11. Lab Studies
- CBC: WBC normal or mildly elevated; lymphopenia is characteristic and prognostic; neutrophilia common [5][7]
- Inflammatory markers: CRP markedly elevated (mean ~175 mg/L), ESR elevated, PCT elevated (often disproportionately high for an "atypical" pathogen) [3][5][30]
- D-dimer: Elevated; independent predictor of severe disease (AUC 0.765) [7][10]
- LDH: Elevated in >70% — marker of tissue injury and severity predictor [5][10]
- Hepatic panel: AST/ALT elevated in majority; hepatic dysfunction in up to 88% [16][31]
- Albumin: Low — hypoalbuminemia common [11][18]
- Electrolytes: Hyponatremia (>50%), hypokalemia, hypocalcemia [5][11][31]
- Renal function: BUN/creatinine may be elevated; AKI in 34% [17]
- CK / BNP: Elevated CK and BNP indicate severe disease and myocardial involvement [11]
- Coagulation: Prolonged PT, elevated fibrinogen and D-dimer in severe cases [9][11]
- Blood urea nitrogen-to-albumin ratio (BAR): AUC 0.88 for predicting AKI [17]
12. Imaging
- Chest CT (preferred): Consolidation (71–100%) and ground-glass opacities are the hallmark findings, typically involving middle and lower lobes. Air bronchograms common [3][7][11]
- Pleural effusion: Present in 34–79% of cases; significantly more common in severe disease [7][11]
- Bilateral involvement: Associated with severe disease (52% severe vs 23% non-severe) [7]
- Chest X-ray: May show unilateral or bilateral infiltrates; can underestimate extent of disease compared to CT
- Atypical presentations: Rarely, pulmonary nodules and cavitary lesions have been reported [32]
- Follow-up imaging: Resolution of infiltrates may take weeks to months (up to 90 days) [1]
- Imaging is not specific — cannot distinguish from Legionella or other atypical pneumonias by imaging alone [28]
13. Special Tests
- Metagenomic next-generation sequencing (mNGS) of BAL fluid — emerging gold standard for definitive diagnosis; results in 48–72 hours [3][5][8]
- Real-time PCR for C. psittaci — faster and more sensitive than serology; lower respiratory specimens (sputum, BAL) far superior to nasopharyngeal swabs (59% vs 7% detection) [21]
- Serology: Complement fixation or microimmunofluorescence (MIF) — requires paired sera (acute and convalescent 2–4 weeks apart); 4-fold rise in titer is diagnostic. Single IgM has poor sensitivity [4][26]
- Culture: Technically difficult, requires BSL-3 facility; not available for routine clinical use [4]
- Stool PCR: May have diagnostic utility (4/5 positive in one outbreak) [21]
- Bronchoscopy: Shows hyperemia, mucosal edema, and congestion; useful for obtaining BAL for mNGS/PCR [3][33]
- CURB-65 or PSI for CAP severity stratification
14. ECG
- Obtain ECG in all hospitalized patients to evaluate for myocarditis or pericarditis [20]
- Findings may include: sinus tachycardia, ST-segment changes, T-wave inversions, conduction abnormalities
- Myocardial injury is an independent risk factor for severe disease (OR 124.3) [9]
- Rare but reported: endocarditis (culture-negative), myocarditis with dilated cardiomyopathy (reversible with treatment), pericarditis [20][29][34]
- Consider echocardiography if troponin/BNP elevated or new murmur detected [34]
15. Assessment
- Psittacosis should be suspected in any patient with atypical CAP + bird/poultry exposure + high fever + failure to improve on beta-lactams [3]
- The classic triad: fever + headache + dry cough with avian exposure history
- Severity ranges from mild self-limited illness to fulminant pneumonia with ARDS and multi-organ failure; 42.6% of diagnosed cases meet severe CAP criteria in multicenter data [5]
- Overall mortality with appropriate treatment: 2.5–5.4%; mortality in severe cases requiring mechanical ventilation: up to 21% [5][7][11]
- Complications: ARDS, respiratory failure, AKI, hepatic dysfunction, myocarditis, endocarditis, meningitis, DIC, venous thrombosis [9][11][17][19]
- Frequently misdiagnosed — median diagnostic delay is 5–12 days from admission [6][11]
16. Treatment Plan
Initial stabilization
- ABCs; supplemental oxygen for hypoxia; early intubation if progressing to ARDS
- IV access, fluid resuscitation for sepsis-like presentations
Antibiotic therapy
- Doxycycline 100 mg IV/PO q12h — first-line; switch to PO when clinically improving [13-14]
- Moxifloxacin 400 mg IV/PO daily — alternative or adjunct in severe cases [3][25]
- Duration: 10–21 days (minimum 10 days; longer courses for severe or complicated disease)
- In pregnancy: azithromycin 500 mg day 1, then 250 mg daily
- Severe/ICU: Consider doxycycline + moxifloxacin combination; tigecycline or omadacycline as rescue options [15-16]
Supportive care
- Mechanical ventilation for respiratory failure (NIV or invasive) [8][11]
- VV-ECMO for refractory hypoxemia [11-12]
- CRRT for AKI [11]
- Corticosteroids: Used in some severe cases (dexamethasone), though evidence is limited [1]
Key pearl: Tetracyclines had a 95.7% effective rate vs 31.0% for fluoroquinolones in one multicenter study, with shorter defervescence time — strongly favoring doxycycline as first-line [5]
17. Disposition
Admission criteria
- Hypoxia (SpO₂ <92%), respiratory distress, or need for supplemental oxygen
- Severe sepsis or hemodynamic instability
- Bilateral infiltrates or large pleural effusions
- Altered mental status
- Significant organ dysfunction (AKI, hepatic injury, myocardial injury)
- Inability to tolerate oral medications
- Meeting criteria for severe CAP (CURB-65 ≥3 or PSI class IV–V)
ICU admission
- Respiratory failure requiring mechanical ventilation
- Shock or vasopressor requirement
- Multi-organ dysfunction
- Elevated D-dimer + lymphopenia + elevated LDH (high-risk triad) [7][10]
Discharge criteria
- Afebrile ≥24–48 hours on oral antibiotics
- Stable oxygenation on room air
- Improving inflammatory markers
- Able to tolerate oral doxycycline
Specialist consultation
- Pulmonology/critical care for severe pneumonia or ARDS
- Infectious disease for diagnostic uncertainty or treatment failure
- Cardiology if myocarditis/endocarditis suspected [20][29]
- Report confirmed cases to local public health authorities (psittacosis is a nationally notifiable disease in the US)
18. Follow Up / Return Precautions
- Follow-up: Outpatient visit in 1–2 weeks after discharge to reassess symptoms and confirm completion of antibiotic course
- Repeat chest imaging: Consider at 4–6 weeks; radiographic resolution may take up to 90 days [1]
- Return precautions — seek immediate care for:
- Worsening dyspnea or chest pain
- Recurrence of high fever
- Confusion or altered mental status
- New swelling in legs (DVT risk given elevated D-dimer)
- Patient counseling:
- Complete the full antibiotic course (do not stop early even if feeling better)
- Avoid dairy/antacids within 2 hours of doxycycline
- Identify and eliminate the avian source — infected birds should be treated by a veterinarian
- Educate on proper hygiene when handling birds (ventilation, masks, handwashing, cage cleaning)
- Expected recovery: Most patients improve within 48–72 hours of appropriate antibiotic therapy; full recovery expected in the majority (94–97%) [5][7]
- Public health: Contact tracing of exposed individuals; environmental sampling of bird sources may be warranted [6][21]
References
1. Circulation of Avian Chlamydia Abortus in the Netherlands and Community-Acquired Pneumonia: An Outbreak Investigation and Retrospective Cohort Study. — Raven S, Heijne M, Koomen J, et al. The Lancet. Infectious Diseases. 2025.
2. Psittacosis Outbreak After Participation in a Bird Fair, Western France, December 2008. — Belchior E, Barataud D, Ollivier R, et al. Epidemiology and Infection. 2011.
3. Clinical, Radiological and Pathological Characteristics of Moderate to Fulminant Psittacosis Pneumonia. — Li X, Xiao T, Hu P, et al. PloS One. 2022.
4. Zoonotic Chlamydophila Psittaci Infections From a Clinical Perspective. — Beeckman DS, Vanrompay DC. Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2009.
5. Clinical Features, Treatment, and Outcome of Psittacosis Pneumonia: A Multicenter Study. — Ni Y, Zhong H, Gu Y, et al. Open Forum Infectious Diseases. 2023.
6. Epidemiological Characteristics and Environmental Surveillance of Human Psittacosis in Lishui City, Zhejiang Province, China (2021-2024). — Chen X, Gong L, Lu Y, et al. Frontiers in Microbiology. 2025.
7. Clinical Features and Prognostic Factors of Chlamydia Psittaci Pneumonia: A Retrospective Study. — Li Y, Zhu H, Zhan Z, et al. Frontiers in Medicine. 2026.
8. Application of Metagenomic Next-Generation Sequencing in the Diagnosis of Severe Pneumonia Caused by Chlamydia Psittaci. — Wu HH, Feng LF, Fang SY. BMC Pulmonary Medicine. 2021.
9. Clinical Characteristics of Chlamydia Psittaci Pneumonia: A Single-Center, Retrospective Study Over 5 Years. — Zhu C, Ye T, Ye C, et al. BMC Infectious Diseases. 2025.
10. Admission Clinical Features Associated With Disease Severity in Psittacosis Pneumonia: A Retrospective Study. — Li J, Xue Y, Cui J, et al. Diagnostic Microbiology and Infectious Disease. 2026.
11. Clinical Characteristics of 14 Cases of Severe Chlamydia Psittaci Pneumonia Diagnosed by Metagenomic Next-Generation Sequencing: A Case Series. — Zhang A, Xia X, Yuan X, et al. Medicine. 2022.
12. V-v ECMO for Severe Chlamydia Psittaci Pneumonia Presenting With Sudden Cardiac Arrest: A Case Report and Literature Review. — Chen J, Sun Y, Luo J, et al. Medicine. 2024.
13. FDA Drug Label. — Updated date: 2025-04-18. Food and Drug Administration.
14. FDA Drug Label. — Updated date: 2025-07-25. Food and Drug Administration.
15. Family Psittacosis Cluster Diagnosed by Metagenomic Next-Generation Sequencing in Hangzhou City, Eastern China: A Case Series. — Sun Z, Xu K, Huo L, Zhang X, Chen B. Medicine. 2026.
16. Clinical Characterization of Chlamydia Psittaci Infections Detected by Targeted Next Generation Sequencing in a Chinese Tertiary Hospital. — Song Y, Feng R, Sun L, et al. Frontiers in Medicine. 2025.
17. Systemic Inflammation, Multi-Organ Injury, and Acute Kidney Risk in Psittacosis Pneumonia: A Biomarker-Driven Clinical Characterization. — Song Y, Li N, Ni W. Frontiers in Cellular and Infection Microbiology. 2025.
18. Clinical and Chest Computed Tomography Features Associated With Severe Chlamydia Psittaci Pneumonia Diagnosed by Metagenomic Next-Generation Sequencing: A Multicenter, Retrospective, Observational Study. — Xu L, Zhao Z, Mai H, et al. Medicine. 2022.
19. A Case of Chlamydia Psittaci Caused Severe Pneumonia and Meningitis Diagnosed by Metagenome Next-Generation Sequencing and Clinical Analysis: A Case Report and Literature Review. — Shi Y, Chen J, Shi X, et al. BMC Infectious Diseases. 2021.
20. ACCF/AHA/CDC Conference Report on Emerging Infectious Diseases and Biological Terrorism Threats. Task Force I: Direct Cardiovascular Implications of Emerging Infectious Diseases and Biological Terrorism Threats. — Baddour LM, Zheng ZJ, Labarthe DR, O'Connor S. Journal of the American College of Cardiology. 2007.
21. Use of Real-Time PCR for Chlamydia Psittaci Detection in Human Specimens During an Outbreak of Psittacosis - Georgia and Virginia, 2018. — McGovern OL, Kobayashi M, Shaw KA, et al. MMWR. Morbidity and Mortality Weekly Report. 2021.
22. Multiple Human-to-Human Transmission From a Severe Case of Psittacosis, Sweden, January-February 2013. — Wallensten A, Fredlund H, Runehagen A. Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin. 2014.
23. Human-to-Human Transmission of Chlamydia Psittaci in China, 2020: An Epidemiological and Aetiological Investigation. — Zhang Z, Zhou H, Cao H, et al. The Lancet. Microbe. 2022.
24. Venous-Arterial Extracorporeal Membrane Oxygenation for Psittacosis Pneumonia Complicated With Cardiogenic Shock: Case Report and Literature Review. — Zhang Y, Hu H, Xu Y, et al. BMC Cardiovascular Disorders. 2024.
25. Psittacosis Caused Severe Community-Acquired Pneumonia Accompanied by Acute Hypoxic Respiratory Failure: A Multicenter Retrospective Cohort Study From China. — Tang X, Wang N, Liu G, et al. BMC Infectious Diseases. 2023.
26. Distinction of Clinical Features and Microbiological Methods Between Chlamydia Psittaci and Legionella Pneumophila Pneumonia Confirmed by Metagenomic Next-Generation Sequencing. — Shi L, Zhang D, Yang Q, Yang J, Zhu H. Annals of Medicine. 2024.
27. Comparison of Clinical Features Between Chlamydia Psittaci and Legionella. — Chen J, Yang L, Liu Y, et al. Frontiers in Medicine. 2025.
28. A Case-Control Study on Chlamydia Psittaci Pneumonia and Legionella Pneumonia. — Gao Y, Lin YJ, Zhang WL, et al. Frontiers in Medicine. 2025.
29. Brief Report: Chlamydia Psittaci Endocarditis Diagnosed by Blood Culture. — Shapiro DS, Kenney SC, Johnson M, et al. The New England Journal of Medicine. 1992.
30. Targeted Next-Generation Sequencing Improves Diagnosis and Antimicrobial Stewardship in Chlamydia Psittaci Pneumonia. — Yao Y, Lai Y, Wu Q, Xu W. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2026.
31. Clinical Characterization and Diagnosis of 14 Patients With Chlamydia Psittaci Pneumonia. — Song L, Liang Q, Chen Y, et al. Diagnostic Microbiology and Infectious Disease. 2025.
32. Chlamydia Psittaci Pneumonia Manifested as Pulmonary Nodules and Cavitary Lesions: A Case Report. — Zhong H, Huang D, Lin Y, et al. BMC Infectious Diseases. 2025.
33. Clinical Characteristics of Five Cases of Chlamydia Psittaci Pneumonia Diagnosed Using Metagenomics Next-Generation Sequencing. — Wang W, Yan CL, Xue QS. Vector Borne and Zoonotic Diseases. 2025.
34. Echocardiographic Follow-Up of Chlamydia Psittaci Myocarditis. — Schinkel AF, Bax JJ, van der Wall EE, Jonkers GJ. Chest. 2000.